Available Technologies
# of Displayed Technologies: 1 / 1
LLL12b: a novel STAT3 inhibitor to treat MS and other autoimmune and inflammatory diseases
TS-038701 —
Modality: Small-molecule prodrug that targets the IL-6/STAT3 signaling pathway
Stage of Development: Extensive in vitro and in vivo efficacy (3 MS models, incl. relapsing-remitting EAE); preliminary safety
Patent Status: Pat. no. 11,420,946 (US); appl. 17/821,286 (US); appl. 18860926.7 (EP); app…
- College: College of Medicine (COM)
- Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
- Licensing Officer: He, Panqing
